Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Bencyclane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.52 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | AQP3 | Q92482 | 1/20 | 0.38 |
| ▸ | AQP1 | P29972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bencyclane SCHEMBL220903 | 1.00 | HRH1 (0.52) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL20505617 | 0.99 | HRH1 (0.51) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL64881 | 0.90 | AQP3 (0.44) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL11215911 | 0.83 | HRH1 (0.38) | HRH1CTSKCTSLCTSBALDH1A1 | |
| Pyritinol SCHEMBL10629435 | 0.80 | HRH1 (0.40) | HRH1CTSKCTSLCTSBALDH1A1 | |
| SCHEMBL11666639 | 0.78 | AQP1 (0.43) | HRH1CTSKCTSLCTSBCHRM2 | |
| SCHEMBL13681480 | 0.77 | AQP3 (0.50) | HRH1CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL11444307 | 0.76 | HRH3 (0.50) | CHRM2CHRM1ALDH1A1KDM4EAQP3 | |
| Etafenone SCHEMBL4715940 | 0.75 | ABCB1 (0.48) | ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL14409639 | 0.75 | AQP3 (0.48) | HRH1CHRM2CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| CN-101820886-A | Bifunctional synthetic molecules | BIOCHEMICS INC | 2010-09-01 | — | — | CN | claimed |
| EP-2167104-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BioChemics, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156758-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BIOCHEMICS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080312296-A1 | Bifunctional synthetic molecules | ADEC PRIVATE EQUITY INVESTMENTS, LLC | 2008-12-18 | — | — | US | claimed |
| WO-2008126088-A2 | ANTI-PYRETIC VASODILATORS | ZACHAR ORON (IL) | 2008-10-23 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-4555398-A | THERMOSETTING OR THERMOPLASTIC RESIN MOLD | CHISSO CORPORATION (JP) | 1985-11-26 | — | — | US | claimed |
| EP-0018773-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING BENCYCLANE FUMARATE, A PROCESS FOR ITS PREPARATION AND AN INCLUSION COMPOUND CONTAINING BENCYCLANE FUMARATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-22 | — | — | EP | claimed |
| US-4352793-A | ANTICONVULSANTS, VASODILATORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-10-05 | — | — | US | claimed |
| EP-0018773-A1 | A pharmaceutical composition containing bencyclane fumarate, a process for its preparation and an inclusion compound containing bencyclane fumarate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312296-A1 | Bifunctional synthetic molecules | PGF, VEGFA, PTGFR | HRH1 251/4885CHRM2 1002/4885CHRM3 781/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | HRH1 1675/4885CHRM2 557/4885CHRM3 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.